Tag Archive for: commercialization

The suite of capabilities combines deep market and patient insights, launch strategy expertise, and rigorous cross-functional execution to ensure relentless alignment throughout the product launch process.

This first-to-market technology gives patient service teams nearly immediate insight into patient coverage from both pharmacy and major medical plans, the potential need for prior authorization support, and any financial responsibilities impacting patient access and speed to treatment.

Urhekar will play a key role on the company’s Executive Committee as he unites 1,600 employees as one team under a single vision, breaking down barriers to faster-connect patients to life-enhancing therapies. All business units — Consulting; Medical; Policy; Value, Evidence and Access; Marketing; and Digital Experience and Technology — will report to Urhekar.

Market access in oncology impacts HCP willingness to write the Rx, ability for the office staff to facilitate clearance of the prior authorizations to access the Rx, and patient affordability to start and stay on therapy over time. Particularly for patients and caregivers who are told they must enter battle with the diagnosis of a solid or squamous tumor type — avoiding delays to the initiation of therapy is vital to helping improve the chances of survival with a meaningful quality of life.

Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.

The partnership supports commitment to providing high-quality products, supply chain continuity, and exceptional customer service.

The agreement is the culmination of a comprehensive review of opportunities available to Syneos Health, including interest from multiple parties with the assistance of independent financial and legal advisors.

The promotion elevates Irish and Evans to the highest level of leadership at Peregrine.

This exclusive licence agreement gives GSK rights to commercialize Brexafemme for vulvovaginal candidiasis and recurrent VVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a life-threatening fungal infection.

Industry innovators and change leaders Neil Matheson, John ‘Zeke’ Czekanski, and Scott Roberts have joined forces under the CiTRUS Health Group umbrella to create a robust, boutique strategic consulting business that blends Scientific & Medical Communications with Market Access.